Related Experiment Videos
Single-dose pharmacokinetics of factor IX evaluated by model-independent methods
G Longo1, S Cinotti, E Filimberti
1Hemophilia Center, Ospedale di Careggi, Florence, Italy.
European Journal of Haematology
|November 1, 1987
Summary
Pharmacokinetic analysis of Factor IX concentrates in hemophilia B patients revealed consistent parameters between Bebulin TIM2 and Preconativ. In vivo recovery was inversely correlated with the volume of distribution.
Area of Science:
- Pharmacology
- Hematology
- Biochemistry
Background:
- Hemophilia B is a genetic bleeding disorder caused by deficiency in Factor IX.
- Factor IX concentrates are crucial for managing hemophilia B, but their pharmacokinetic profiles require detailed study.
- Understanding the pharmacokinetics of different Factor IX concentrates ensures optimal treatment efficacy.
Purpose of the Study:
- To evaluate and compare the pharmacokinetic parameters of two Factor IX concentrates, Bebulin TIM2 and Preconativ, in hemophilia B patients.
- To investigate the relationship between in vivo recovery and volume of distribution for Factor IX.
- To assess the suitability of one-compartment versus two-compartment models for describing Factor IX decay curves.
Main Methods:
- Pharmacokinetic data from 13 hemophilia B subjects receiving a single dose of either Bebulin TIM2 or Preconativ were analyzed.
- Model-independent methods were used to estimate key pharmacokinetic parameters including clearance, mean residence time, and volume of distribution.
- Model-dependent compartmental analysis was performed to compare one-compartment and two-compartment models for decay curve fitting.
Main Results:
- Estimated pharmacokinetic parameters (mean +/- SD) were: clearance (4.99 +/- 2.01 ml/h/kg), mean residence time (22.9 +/- 10.6 h), and volume of distribution (99.9 +/- 35.5 ml/kg).
- In vivo recovery (59.8% +/- 16.9%) showed an inverse correlation with the volume of distribution.
- No significant pharmacokinetic differences were observed between Bebulin TIM2 and Preconativ. A two-compartment model provided a better fit than a one-compartment model in 53.8% of cases, but this was statistically significant in only 15.4%.
Conclusions:
- Bebulin TIM2 and Preconativ exhibit comparable pharmacokinetic profiles in hemophilia B patients.
- The volume of distribution is a critical factor influencing the in vivo recovery of Factor IX concentrates.
- A one-compartment model may be sufficient for describing Factor IX pharmacokinetics in many hemophilia B patients, simplifying analysis.